Further studies demonstrated that aberrant expression of FOXD3-AS1 is closely associated to clinicopathological characteristics, such as tumor size, tumor grade, distant lymph node metastasis, differentiation of tumor tissues, overall survival, progression-free survival, and survival time of patients (Table 1). Here, FOXD3 is linked to neoplasm.